S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Galectin Therapeutics Issues Statement on GR-MD-02 Development Program|
|Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis|
|EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Galectin Therapeutics, Inc. -- GALT|
|SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT|
|Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Galectin Therapeutics, Inc. (GALT) to Contact the Firm|
|Galectin Therapeutics Added to Russell 2000 Index|
|Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma|
|Ryan & Maniskas, LLP Announces Investigation of Galectin Therapeutics, Inc.|
|Harwood Feffer LLP Announces Investigation of Galectin Therapeutics Inc.|
|SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics, Inc. - GALT|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
Click above to view more mutual fund data and stats for galt - Galectin Therapeutics Inc.